Data as of Q4 2025 (Dec 31, 2025)

Omega Fund Management, LLC

•CIK: 1637359•Filing: Q4 2025

**Omega Fund Management, LLC** manages $287M across a concentrated portfolio of 11 positions. The fund exhibits significant conviction in its top holdings, led by NUVB, representing $72.4M, followed by BBOT at $41.2M and BBNX at $40.1M. These top three names alone account for over 52% of the reported assets. Omega's current allocation suggests a focused, high-conviction approach within its investment mandate.

Total AUM
$286.5M
QoQ Performance
+28.9%
Positions
11
Top 10 Concentration
99.2%
Latest Filing
Q4 2025

Top Holdings Allocation

NUVB
BBOT
BBNX
BCAX
Kest
UPB
NUVB25.3%
BBOT14.4%
BBNX14.0%
BCAX12.9%
Kestra12.7%
UPB12.6%
ENGN2.8%
ALMS2.2%

📈 Biggest Buys

ENGN
enGene Holdings Inc.
+66.5%
2.8% of portfolio

📉 Biggest Sells

BBNX
Beta Bionics Inc.
-31.5%
14.0% of portfolio
—
Kestra Med Technologies Ltd
-16.5%
12.7% of portfolio
NUVB
Nuvation Bio
-8.5%
25.3% of portfolio
UPB
Upstream Bio Inc.
-2.2%
12.6% of portfolio

Sector Breakdown

Other100.0%

🚪 Exited Positionssold since Q3 2025

ENGNW
enGene Holdings Inc.
SOLD
$63.4K

Changes from Q3 2025

↑1 increased
↓4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

📌 Top Holdings

NUVB25.3%
Nuvation Bio
$72.4M
BBOT14.4%
BridgeBio Oncology Therapeutics Inc.
$41.2M
BBNX14.0%
Beta Bionics Inc.
$40.1M
BCAX12.9%
Bicara Therapeutics Inc.
$37.1M
UPB12.6%
Upstream Bio Inc.
$36.0M

⚖️ Compare Fund

Compare this fund's holdings with other hedge funds.

🎯 Fund Movement Signals

See AI-analyzed fund movement signals and accumulation patterns.

👤 Insider Trading

See what corporate insiders are buying and selling.